Mind + Muscle

technical minds + legal muscle


dig deep

Clinical Trials in Biopharma

  • 06.17.11
  • Eric K. Steffe
  • Life Sciences Intellectual Property Review 2011

According to a recent study, biotechnology companies and universities discovered 42 percent of all innovative drugs approved by the FDA between 1998 and 2007. Biotechnology companies, however, are unprepared for the intellectual property issues that arise as a promising drug progresses through clinical trials. Eric Steffe explains. To view the full article, download the attached PDF.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.